Abstract
This paper reports the synthesis of a panel of small molecules with arylamides and arylsulfonamides groups and their biological activity in inhibiting nucleotide exchange on human Ras. The design of these molecules was guided by experimental and molecular modelling data previously collected on similar compounds. Aim of this work is the validation of the hypothesis that a phenyl hydroxylamine group linked to a second aromatic moiety generates a pharmacophore capable to interact with Ras and to inhibit its activation. In vitro experiments on purified human Ras clearly show that the presence of an aromatic hydroxylamine and a sulfonamide group in the same molecule is a necessary condition for Ras binding and nucleotide exchange inhibition. The inhibitor potency is lower in molecules in which either the hydroxylamine has been replaced by other functional groups or the sulfonamide has been replaced by an amide. In the case both these moieties, the hydroxylamine and sulfonamide are absent, inactive compounds are obtained.
Keywords: Ras, anticancer agents, computational chemistry, structure-activity relationship
Current Cancer Drug Targets
Title: Structure-Activity Studies on Arylamides and Arysulfonamides Ras Inhibitors
Volume: 10 Issue: 2
Author(s): S. Colombo, A. Palmioli, C. Airoldi, R. Tisi, S. Fantinato, S. Olivieri, L. De Gioia, E. Martegani and F. Peri
Affiliation:
Keywords: Ras, anticancer agents, computational chemistry, structure-activity relationship
Abstract: This paper reports the synthesis of a panel of small molecules with arylamides and arylsulfonamides groups and their biological activity in inhibiting nucleotide exchange on human Ras. The design of these molecules was guided by experimental and molecular modelling data previously collected on similar compounds. Aim of this work is the validation of the hypothesis that a phenyl hydroxylamine group linked to a second aromatic moiety generates a pharmacophore capable to interact with Ras and to inhibit its activation. In vitro experiments on purified human Ras clearly show that the presence of an aromatic hydroxylamine and a sulfonamide group in the same molecule is a necessary condition for Ras binding and nucleotide exchange inhibition. The inhibitor potency is lower in molecules in which either the hydroxylamine has been replaced by other functional groups or the sulfonamide has been replaced by an amide. In the case both these moieties, the hydroxylamine and sulfonamide are absent, inactive compounds are obtained.
Export Options
About this article
Cite this article as:
Colombo S., Palmioli A., Airoldi C., Tisi R., Fantinato S., Olivieri S., De Gioia L., Martegani E. and Peri F., Structure-Activity Studies on Arylamides and Arysulfonamides Ras Inhibitors, Current Cancer Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/156800910791054185
DOI https://dx.doi.org/10.2174/156800910791054185 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cyclooxygenase-2 Inhibition and Gastric Cancer
Current Pharmaceutical Design Nano-Metal Organic Frame Work an Excellent Tool for Biomedical Imaging
Current Medical Imaging Chemotherapy Resistance in Breast Cancer
Current Cancer Therapy Reviews Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design Beta-Caryophyllene Suppresses Ovarian Cancer Proliferation by Inducing Cell Cycle Arrest and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.
Current Stem Cell Research & Therapy Dual-purpose Injectable Doxorubicin Conjugated Alginate Gel Containing Polycaprolactone Microparticles for Anti-Cancer and Anti-Inflammatory Therapy
Current Drug Delivery Development and Tailoring of Hybrid Lipid Nanocarriers
Current Pharmaceutical Design Cell Cycle Re-Entry in Alzheimers Disease: A Major Neuropathological Characteristic?
Current Alzheimer Research Theranostic Platforms Proposed for Cancerous Stem Cells: A Review
Current Stem Cell Research & Therapy Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
Current Aging Science GIST and Breast Cancer: 3 Case Reports and a Review of the Literature
Current Cancer Therapy Reviews Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Effects of Biphenyl Sulfonylamino Methyl Bisphosphonic Acids on Porphyromonas Gingivalis and Cytokine Secretion by Oral Epithelial Cells
Medicinal Chemistry Potential Future of New Glutamate Agonists and Antagonists Development
Anti-Cancer Agents in Medicinal Chemistry 3D-QSAR Methodologies and Molecular Modeling in Bioinformatics for the Search of Novel Anti-HIV Therapies: Rational Design of Entry Inhibitors
Current Bioinformatics Cancer Regulator MicroRNA: Potential Relevance in Diagnosis, Prognosis and Treatment of Cancer
Current Medicinal Chemistry Phosphotyrosine Phosphatases in Cancer Diagnostic and Treatment
Recent Patents on DNA & Gene Sequences Molecular Beacon Aptamers for Protein Monitoring in Real-Time and in Homogeneous Solutions
Current Proteomics Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
Current Cancer Therapy Reviews